Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma

被引:66
作者
Leitao, MM
Soslow, RA
Baergen, RN
Olvera, N
Arroyo, C
Boyd, J
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[3] Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Dept Pathol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
关键词
TP53; p53; tumor suppressor gene; early stage; ovarian cancer;
D O I
10.1016/j.ygyno.2004.01.043
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The early natural history of epithelial ovarian carcinoma remains poorly understood. Mutation of the TP53 gene is common in advanced-stage (III-IV) ovarian cancers, but less well described in early stage (I-II) tumors. The purpose of this study was to perform a comprehensive analysis of TP53 mutation and p53 expression status in early stage ovarian carcinomas. Methods. Seventy-three cases of various histologic types, including 46 stage I and 27 stage II tumors, were subjected to direct sequence analysis of the entire TP53 coding region and exon-intron junctions as well as immunohistochemical assessment of p53 expression. Results. Overall, mutations were identifi--d in 24 of 73 (34%) cases. However, a significant difference in the distribution of mutations among histologic types was observed; TP53 mutations were present in 14 of 21 (67%) serous cancers and II of 52 (21%) non-serous cancers (P = 0.0002). Mutations were equally common between stage I and stage II tumors of serous histology. With respect to the correlation between TP53 mutation and p53 immunopositivity, the sensitivity (58%), specificity (71%), positive predictive value (64%), and negative predictive value (83%) were not sufficiently robust to justify use of p53 expression as a surrogate or screen for mutation. Conclusions. These data indicate that TF53 mutation is common in early stage ovarian carcinomas of serous histology, with a mutation frequency comparable to that reported for advanced-stage tumors, and is therefore likely to occur early in the progression of the most common histologic variant of ovarian carcinoma. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:301 / 306
页数:6
相关论文
共 18 条
[1]  
Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO
[2]  
2-H
[3]  
Boyd JA, 2000, PRINCIPLES PRACTICE, P103
[4]  
Casey G, 1996, ONCOGENE, V13, P1971
[5]  
GREENBLATT MS, 1994, CANCER RES, V54, P4855
[6]  
Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1
[7]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[8]   A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors [J].
Kmet, LM ;
Cook, LS ;
Magliocco, AM .
CANCER, 2003, 97 (02) :389-404
[9]   Clinicopathologic analysis of early-stage sporadic ovarian carcinoma [J].
Leitao, MM ;
Boyd, J ;
Hummer, A ;
Olvera, N ;
Arroyo, CD ;
Venkatraman, E ;
Baergen, RN ;
Dizon, DS ;
Barakat, RR ;
Soslow, RA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (02) :147-159
[10]   p53, the cellular gatekeeper for growth and division [J].
Levine, AJ .
CELL, 1997, 88 (03) :323-331